1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program

Autor:	Olivier Dereure, C. Jarvis, Nicolas Meyer, F. Brunet-Possenti, Laurent Mortier, J.-J. Grob, Florent Grange, C. Dutriaux, E. Scherrer, M.-T. Leccia, E-M. Neidhardt, Caroline Robert, A. Spampinato, F. Aubin, L. Verdoni, Philippe Saiag, Nora Kramkimel, Laurent Machet, A-B. Duval-Modeste, L. Benmahammed-Bellagha
Rok vydání:	2021
Předmět:	medicine.medical_specialty Oncology Horizon (archaeology) business.industry General surgery medicine Hematology Pembrolizumab business Advanced melanoma
Zdroj:	Annals of Oncology. 32:S895
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1465
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ac3d0b71c3636ecb3af6e8951229878e https://doi.org/10.1016/j.annonc.2021.08.1465 Zobrazit plný text záznamu